|
|
AmitriptylineThe elimination of leprosy, although defined as a reduction of prevalence below a particular level, depends to a large extent on a reduction of the occurrence of new cases. While a small number of countries show a downward trend in annual case detection, others show a steady or upward trend. As attaining leprosy elimination depends very much on having reliable information on case detection, it is important to validate the case detection figures both through a review of registers as well assessment of the patients themselves. Programme-wide validation is most desirable but not always possible. However, in practical terms it is possible to get an insight into the situation through the validation of information on case detection, at least on a sample basis. While validation of wrong or over-diagnosis by the checking of records and patients is relatively easy to carry out, the validation of missing cases or under-diagnosis is not, as it involves the examination of large numbers of community members. Wrong or over-diagnosis can be validated through sample checks of recently diagnosed cases applying standard procedures. During such checks, it should be possible to have a higher level of specificity of diagnosis including the collection of information on nerve damage, skin smears, and a detailed clinical picture. The expected outcome of any validation exercise on case detection is to obtain a clearer understanding of the true situation of disease occurrence in any given area, and to sensitize health workers to possible problems of over- and under-detection so that they can perform more effectively in the future. As leprosy progresses towards being a low-prevalence disease, it is important to find tools and procedures to maintain a high level of specificity for confirming the diagnosis of a case of leprosy. Bryant, R.A., Harvey, A.G., Dang, S.T., et al 1998 ; Treatmentof acutestressdisorder: acomparisonofcognitivebehavioural of Consulting and Clinical Psychology, 66, 862866. Burghardt, N.S., Sullivan, G.M., McEwen, B.S., et al 2004 ; The selective serotonin reuptake inhibitor citalopram increases Psychiatry, 55, 11711178. Butterfield, M.I., Becker, M.E., Connor, K.M., et al 2001 ; apilot study.International Clinical Psychopharmacology, 16, 197203. Cohen, J. 1988 ; Statistical Power Analysis for the Behavioural Davidson, J., Kudler, H., Smith, R., et al 1990 ; Treatmentofposttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry, 47, 259266. Davidson, J.R. T., Rothbaum, B. O., vander Kolk, B.A., et al 2001a ; Multicenter, double-blind comparison of sertraline Archive of General Psychiatry, 58, 485492. Davidson, J., Pearlstein, T., Londborg, P., et al 2001b ; Efficacyof resultsofa28weekdoubleblind, placebo-controlled study.American Journal of Psychiatry, 158, 19741981. Davidson, J.R.T., Weisler, R.H., Butterfield, C.D.C., et al 2003 ; apilot trial.Society of Biological Psychiatry, 53, 188191. Davidson, J., Baldwin, D., Stein, D. J., et al 2006 ; Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry, 63, 11581165. Duff, G. 2004 ; Safety of Selective Serotonin Reuptake Inhibitor Antidepressants mitteeonSafetyofMedicines. : info.doh.gov doh embroadcast.nsf vwDiscussionAll 9AA9EC56B07B3B4F80256F61004BAA88 Ehlers, A., Clark, D.M., Hackmann, A., et al 2003 ; Arandomized aself-helpbooklet, and stressdisorder.Archives of General Psychiatry, 60, 10241032. Friedman, M. J., Davidson, J. R. T. & Mellman, T. A. 2000 ; Pharmacotherapy. In Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies eds E. B. Foa, T. M. Keane & M. J. Freidman ; , pp. 84105.GuilfordPress. Gilbertson, M. W., Shenton, M. E., Ciszewski, A., et al 2002 ; topsychologicaltrauma.Nature Neuroscience, 5, 12421247. Hamner, M.B., Faldowski, R.A., Ulmer, H.G., et al 2003 ; a symptoms.International Clinical Psychopharmacology, 18, Kessler, R.C., Sonnega, A., Bromet, E., et al 1995 ; Posttraumatic of General Psychiatry, 52, 10481060. Kosten, T.R., Frank, J.B., Dan, E., et al 1991 ; Pharmacotherapyfor Journal of Nervous and Mental Disease, 179, 366370. Marshall, R.D., Beebe, K.L., Oldham, M., et al 2001 ; Efficacy afixeddose, placebo-controlledstudy.American Journal of Psychiatry, 158, 19821988. Martenyi, F., Brown, E. B., Zhang, H., et al 2002 ; Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry, 63, 199205. Mellman, T.A., Bustamante, V., David, D., et al 2002 ; Hypnotic medication in the aftermath of trauma. Journal of Clinical Psychiatry, 63, 11831184. National Collaborating Centre for Mental Health 2005 ; Posttraumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care. National Clinical Practice Guideline Number 26.Gaskell&BritishPsychological Society. Ozer, E.J., Best, S.R., Lipsey, T.L., et al 2003 ; Predictorsofposttraumatic stress disorder and symptoms in adults: a metaanalysis.Psychological Bulletin, 129, 5273. In Scotland, the number of first-ever hospitalisations for atrial fibrillation increased two-fold between 1986 and 1995. Although the age of patients has progressively increased during this period, short and medium casefatality rates have declined, especially in men. This may partly reflect better treatment. However, changing admission thresholds and other factors could also have led to an apparent improvement in prognosis. Nevertheless, medium-term case fatality remains substantial after a first ever admission to hospital with AF. Short term 30 day ; casefatality fell from 4.0% to 3.1% in men p 0.001 ; and 4.1% to 3.8% in women p 0.01 ; . Medium term case-fatality 31day to 2-year ; fell from 25% to 22% in men and 27% to 25% in women p for both 0.001 ; i. DSM-IV criteria for major depressive disorder on two consecutive visits 11 days apart. In the double-blind phase, patients receiving continued EMSAM selegiline transdermal system ; experienced a significantly longer time to relapse. An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, gender, or race. INDICATIONS AND USAGE EMSAM is indicated for the treatment of major depressive disorder. The efficacy of EMSAM in the treatment of major depressive disorder was established in 6- and 8-week placebocontrolled trials of outpatients with diagnoses of DSM-IV category of major depressive disorder see Clinical Efficacy Trials ; . A major depressive episode DSM-IV ; implies a prominent and relatively persistent nearly every day for at least 2 weeks ; depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicide attempt or suicidal ideation. The benefit of maintaining patients with major depressive disorder on therapy with EMSAM after achieving a responder status for an average duration of about 25 days was demonstrated in a controlled trial see Clinical Efficacy Trials under CLINICAL PHARMACOLOGY ; . The physician who elects to use EMSAM for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient see DOSAGE AND ADMINISTRATION ; . The antidepressant action of EMSAM in hospitalized depressed patients has not been studied. CONTRAINDICATIONS EMSAM is contraindicated in patients with known hypersensitivity to selegiline or to any component of the transdermal system. EMSAM is contraindicated with selective serotonin reuptake inhibitors SSRIs, e.g., fluoxetine, sertraline, and paroxetine dual serotonin and norepinephrine reuptake inhibitors SNRIs, e.g., venlafaxine and duloxetine tricyclic antidepressants TCAs, e.g., imipramine and amitriptyline bupropion hydrochloride; meperidine and analgesic agents such as tramadol, methadone and propoxyphene; the antitussive agent dextromethorphan; St. John's wort; mirtazapine; and cyclobenzaprine. EMSAM should not be used with oral selegiline or other MAO inhibitors MAOIs e.g., isocarboxazid, phenelzine, and tranylcypromine ; see WARNINGS ; . Carbamazepine and oxcarbazepine are contraindicated in patients taking selegiline see PRECAUTIONS, Drug Interactions ; . As with other MAOIs, EMSAM is contraindicated for use with sympathomimetic amines, including amphetamines as well as cold products and weight-reducing preparations that contain vasoconstrictors e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine ; . As with other MAOIs, patients taking EMSAM should not undergo elective surgery requiring general anesthesia. Also, they should not be given cocaine or local anesthesia containing sympathomimetic vasoconstrictors. EMSAM should be discontinued at least 10 days prior to elective surgery. If surgery is necessary sooner, benzodiazepines, mivacurium, rapacuronium, fentanyl, morphine, and codeine may be used cautiously. As with other MAOIs, EMSAM is contraindicated for use in patients with pheochromocytoma. EMSAM is an irreversible MAO inhibitor. As a class, these compounds have been associated with hypertensive crises caused by the ingestion of foods containing high amounts of tyramine. In its entirety, the data for EMSAM 6 mg 24 hours support the recommendation that a modified diet is not required at this dose. Due to the more limited data available for EMSAM 9 mg 24 hours and 12 mg 24 hours, patients receiving these doses should follow Dietary Modifications Required for Patients Taking EMSAM 9 mg 24 hours and 12 mg 24 hours. See WARNINGS and PRECAUTIONS, Drug Interactions, Tyramine. ; WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder MDD ; , both adult and pediatric, may experience worsening of their depression and or the emergence of suicidal ideation and behavior suicidality ; or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. There has been a long-standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients. Antidepressants increased the risk of suicidal thinking and behavior suicidality ; in short-term studies in children and adolescents with Major Depressive Disorder MDD ; and other psychiatric disorders. Pooled analyses of short-term placebo-controlled trials of nine antidepressant drugs SSRIs and others ; in children and adolescents with MDD, OCD, or other psychiatric disorders a total of 24 trials involving over 4400 patients ; have revealed a greater risk of adverse events representing suicidal behavior or thinking suicidality ; during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. There was considerable variation in risk among drugs, but a tendency toward an increase for almost all drugs studied. The risk of suicidality was most consistently observed in the MDD trials, but there were signals of risk arising from trials in other psychiatric indications obsessive compulsive disorder and social anxiety disorder ; as well. No suicides occurred in these trials. It is unknown whether the suicidality risk in pediatric patients extends to longer-term use, i.e., beyond several months. It is also unknown whether the suicidality risk extends to adults. All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Such observation would generally include at least weekly face-to-face contact with patients or their family members or caregivers during the first 4 weeks of treatment, then every other week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks. Additional contact by telephone may be appropriate between face-to-face visits. Adults with MDD or co-morbid depression in the setting of other psychiatric illness being treated with antidepressants should be observed similarly for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia psychomotor restlessness ; , hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms. Families and caregivers of pediatric patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for EMSAM should be written for the smallest quantity consistent with good patient management, in order to reduce the risk of overdose. Families and caregivers of adults being treated for depression should be similarly advised. Screening Patients for Bipolar Disorder A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed though not established in controlled trials ; that treating such an episode with an antidepressant alone may increase the. Tricyclics Antimuscarinic and cardiovascular side-effects are common. Dose titration is essential to avoid risk of postural hypotension. Caution with use in elderly patients and those with cardiovascular disease. Therapeutic dose range is equivalent to amitriptyline 75 150mg daily. Amitriotyline and trimipramine are more sedating. Amirriptyline is most dangerous in overdose. Clomipramine has particular indication in phobic and obsessional states. Lofepramine has lower incidence of antimuscarinic, cardiovascular and sedative side-effects but reports of hepatic abnormalities. Kochar, D. K., P. Garg, et al. 2005 ; . "Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study." Qjm: Monthly Journal of the Association of Physicians 98 1 ; : 29-34. Kochar, D. K., N. Jain, et al. 2002 ; . "Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study." Acta Neurologica Scandinavica 106 5 ; : 248-52. Kochar, D. K., N. Rawat, et al. 2004 ; . "Sodium valproate for painful diabetic neuropathy: A randomized double-blind placebo-controlled study." Qjm: Monthly Journal of the Association of Physicians 97 1 ; : 33-38. Leijon, G. and J. Boivie 1989 ; . "Central post-stroke pain--a controlled trial of amitriptyline and carbamazepine." Pain 36 1 ; : 27-36. Lesser, H., U. Sharma, et al. 2004 ; . "Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial." Neurology 63 11 ; : 2104-10. Levendoglu, F., C. O. Ogun, et al. 2004 ; . "Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury." Spine 29 7 ; : 743-51. Max, M. B., S. C. Schafer, et al. 1988 ; . "Amitriptyline, but not lorazepam, relieves postherpetic neuralgia." Neurology 38: 1427-1432. McCleane, G. 1999 ; . "200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial." Pain 83 1 ; : 105-7. McCleane, G. J. 1999 ; . "Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study." Anesthesia & Analgesia 89 4 ; : 985-8. Morello, C. M., S. G. Leckband, et al. 1999 ; . "Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain." Archives of Internal Medicine 159 16 ; : 1931-7. Nicol, C. F. 1969 ; . "A four year double-blind study of tegretol in facial pain." Headache 9 1 ; : 54-7. Pandey, C. K., M. Raza, et al. 2005 ; . "The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome patients in the intensive care unit." Anesthesia & Analgesia 101 1 ; : 220-5. Raskin, P., P. D. Donofrio, et al. 2004 ; . "Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects." Neurology 63 5 ; : 865-73. Rice, A. S. C., S. Maton, et al. 2001 ; . "Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study." Pain 94 2 ; : 215-224. Richter, R. W., R. Portenoy, et al. 2005 ; . "Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial." Journal of Pain 6 4 ; : 253-60. Rockliff, B. W. and E. H. Davis 1966 ; . "Controlled sequential trials of carbamazepine in trigeminal neuralgia." Archives of Neurology 15 2 ; : 129-36. Rosenstock, J., M. Tuchman, et al. 2004 ; . "Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial." Pain 110 3 ; : 628-38. Rowbotham, M., N. Harden, et al. 1998 ; . "Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial." JAMA 280 21 ; : 1837-42. Rull, J. Q., R; Gonzalez-Millan, H; Lozano Castenada, O 1969 ; . "Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind crossover study." Diabetologia 5: 215-220. Sabatowski, R., R. Galvez, et al. 2004 ; . "Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial." Pain 109 1-2 ; : 26-35. Saudek, C. D., S. Werns, et al. 1977 ; . "Phenytoin in the treatment of diabetic symmetrical polyneuropathy." Clinical Pharmacology & Therapeutics 22 2 ; : 196-9. Scottish Medicines Consortium "Adivice following an independent review panel Pregabalin No.157 05, 7 July 2006 ; ." On scottishmedicines smc , accessed on 18 May 2007. Serpell, M. G. and Neuropathic pain study group 2002 ; . "Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial." Pain 99 3 ; : 557-66. Siddall, P. J., M. J. Cousins, et al. 2006 ; . "Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial." Neurology 67 10 ; : 1792-800. Simpson, D. A. 2001 ; . "Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy." Journal of Clinical Neuromuscular Disease 3 2 ; : 53-62. Simpson, D. M., J. C. McArthur, et al. 2003 ; . "Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial." Neurology 60 9 ; : 1508-14. Simpson, D. M., R. Olney, et al. 2000 ; . "A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy." Neurology 54 11 ; : 2115-9 and abilify. Other drugs that may be considered are pizotifen and amitriptyline. Ami5riptyline may be particularly useful if there is co-existant sleep disturbance and or tension type headache. Prophylaxis should be given for 3-6 months, then consideration given to gradual withdrawal if there has been a good response. 4.7.4.3 Drug treatment of cluster headache a ; acute attacks. References: Peles D, Schreiber S, and Adelson M, Tricyclic antidepressant abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment MMT ; . Eur Neuropsychopharmacol. 2008 Mar; 18 3 ; : 188-93. Prahlow JA, Landrum JE. Amitriptjline abuse and misuse. J Forensic Med Patho. 2005 Mar; 26 1 ; : 86-8. Ashton CH and Young AH, Selective Serotonin Reuptake Inhibitors SSRIs ; : Past Present and Future, Chapter 5, Ed. Claire Stanford, University College London, 1999. Available at: : benzo ssri Hepburn S, Harden J, Grieve JHK , Hiscox J, Deliberate misuse of tricyclic antidepressants by intravenous drug users case studies and report. SMJ 2006 50 3 ; : 131-133 and anafranil. Telavancin is a parenterally administered semisynthetic glycopeptide that has good activity against MRSA MIC90 0.25 mcg ml ; .64 Its potential for inducing resistance is low: in a study reported at the 2006 ICAAC, no resistant strains of VRSA, vancomycin-intermediate S aureus VISA ; , MRSA, nor several other pathogens arose after 10 days of serial passage in the presence of sub-MIC levels of telavancin.65 Clinically, telavancin was compared with vancomycin for SSSIs in 2 phase 3 trials involving a total of 1867 patients. In the subgroup of patients with MRSA infections, clinical cure rates were 90.6% versus 86.4% for telavancin and vancomycin, respectively P .06 ; . In an earlier phase 2 trial, 39 5 patients in the telavancin group experienced increases in serum creatinine 5% vs 0% ; and in corrected QT QTc ; intervals 6 patients vs 1 patient ; , but no cardiac adverse events were associated with the. W E L lifestyle dietary supplement, adultsStake or as directed by healthcare professional. EXTERNAL USE ONLY. AVOID CONTACT WITH WARNING: FOR and luvox. P. J. LUSTMAN et al. hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 4: 285-294, 1993 Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction: Impact on 6-month survival. JAMA 270: 1819-1825, 1993 Ladwig KH, Kiesser M, Donig J, et al.: Affective disorders and survival after acute myocardial infarction. Eur Heart J 12: 959964, 1991 Kennedy GJ, Hofer MA, Cohen D, et al.: Significance of depression and cognitive impairment in patients undergoing programmed stimulation of cardiac arrythmias. Psychosom Med 49: 410-421, 1987 Lloyd CE, Matthews KA, Wing RR, et al.: Psychosocial factors and complications of IDDM: The Pittsburgh Epidemiology of Diabetes Complications: Study VIII. Diabetes Care 15: 166172, 1992 Robinson N, Fuller H, Edmeades SP: Depression and diabetes. Diabetic Med 5: 268-274, 1988 Carney RM, Freedland KE, Lustman PJ, et al.: Depression and coronary disease in diabetic patients: A 10-year follow-up. Psychosom Med 56: 149, 1994 Smith GR Jr, Monson RA, Ray DC: Psychiatric consultation in somatization disorder: A randomized controlled study. N Engl J Med 314: 1407-1413, 1986 Mumford E, Schlesinger HJ, Glass GV: A critical review and indexed bibliography of the literature up to 1978 on the effects of psychotherapy on medical utilization: Report to NIMH [abstract]. National Institutes of Mental Health, Rockville, MD Contract-MH-77-0049: 1978 Fawzy FI, Fawzy NW, Hyun CS, et al.: Malignant melanoma: Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 50: 681-689, 1993 Spiegel D, Bloom JR, Kraemer HC, et al.: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2: 888-891, 1989 Frasure-Smith N, Prince R: The ischemic heart disease life stress monitoring program: Impact on mortality. Psychosom Med 47: 431-445, 1985 Max MB, Culnane M, Schafer SC, et al.: Maitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37: 589-596, 1987 Turkington RW: Depression masquerading as diabetic neuropathy. JAMA 243: 1147-1150, 1980 Depression Guideline Panel: Depression in primary care. Vol. 5. Detection, Diagnosis and Treatment [abstract]. Department of Health and Human Services, Rockville, MD, AHCPR No. 93: 0550: 1993 DCCT, The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-985, 1993 Morisake N, Watanabe S, Kobayashi J, et al.: Diabetic control and progression of retinopathy in elderly patients: Five-year follow-up study. J Geriatr Soc 42: 142-145, 1994 Lustman PJ: Anxiety disorders in adults with diabetes mellitus. Psychiatr Clin North 11: 419-432, 1988 Finestone DH, Weiner RD: Effects of ECT on diabetes mellitus: An attempt to account for conflicting data. Acta Psychiatr Scand 70: 321-326, 1984 Gupta B, Awasthi A, Jaju BR: Effect of acute and chronic imipramine treatment on glucose homeostasis. Indian J Med Res 96: 65-71, 1992 Kathol RG, Jaeckle R, Wysham C, Sherman BM: Imipramine effect on hypothalamic-pituitary-adrenal axis response to hypoglycemia. Psychiatry Res 41: 45-52, 1992 Potter van Loon BJ, Radder JK, Frolich M, et al.: Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int J Obes 16: 79-85, 1992 Gray DS, Fujioka K, Devine W, et al.: Fluoxetine treatment of the obese diabetic. Int J Obes 16: 193-198, 1992! THE CURE FOR ALL CANCERS Dampen your other hand by making a fist and dunking your knuckles into the wet paper towel in the saucer. You will be using the area on top of the first knuckle of the forefinger or middle finger to learn the technique. Become proficient with both. Immediately after dunking your knuckles dry them on a paper towel folded in quarters and placed beside the saucer. The degree of dampness of your skin affects the resistance in the circuit and is a very important variable that you must learn to keep constant. Make your probe as soon as your knuckles have been dried within two seconds ; since they begin to air dry further immediately. With the handhold and probe both in one hand press the probe against the knuckle of the other hand, keeping the knuckles tightly bent. Press lightly at first, then harder, taking one second. Count it out as "a thousand and one." Repeat the probe a half second later at the same location. There is an additive effect. The first probe opens your cells' conductance channels. The second probe tests to hear if they are indeed open.; These are considered the two halves of a single complete probe. All of this takes less than three seconds. Don't linger because your body will change and your next probe will be affected. Subsequent probes are made in exactly the same way. As you develop skill, your probes will become identical. Plan to practice for one to two hours each day. It takes most people at least twelve hours of practice in order to be so consistent with their probes that they can hear the slight difference when the circuit is resonant. For reference you may wish to use a piano. The starting sound when you touch down on the skin should be F, an octave and a half above middle C. The sound rises to a C you press to the knuckle bone, then slips back to B, then back up to Csharp as you complete the second half of your first probe. If you have a multitester you can connect it in series with the handhold or probe: the current should rise to about 50 mi and keppra! Soho Theatre, 21 Dean Street. 11th 15th July at 9.30pm. Tel: 0870 429 6883. Performing after a six-year gap and having put his Divine David persona to bed, the inner David Hoyle for me, the most fascinating performer on the planet bares his soul, Unmissable! BLACK COMEDY. Erotonin 5-HT ; is a neurotransmitter with neurons located in the raphe nuclei. Serotonin neurons play a part in sleepwakefulness cycles, mood, emotional and food behaviours, and thermoregulation.1 Serotonin syndrome is the result of overstimulation of 5-HT1A receptors Fig. 1 ; by selective serotonin reuptake inhibitors SSRIs ; , tricyclic antidepressants TCAs ; , monoamine oxidase inhibitors MAOI ; or other serotonergic agents.25 The use of SSRIs is related to the frequency of the syndrome.2, 3 Regardless of age or sex, onset is observed within 24 hours following the administration or overdose of a serotonergic agent.2, 4 Serotonin syndrome is characterized by a triad of mental, autonomic and neurological disorders.24, 68 Serotonin syndrome is confirmed by the presence and bupropion. 5. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999; 14: 329337 Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656663 Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. J Geriatr Psychiatry 2002; 10: 541550 Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 6373 Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001; 62: 358361 Guelfi JD, Anssear M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21: 425431 Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001; 62: 413420 Thase ME, Nierenberg AA, Keller MB, et al. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001; 62: 782788 Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345350 Sanchez C, Hogg S. The antidepressant effect of citalopram resides in the S-enantiomer Lu 26-054 ; . Biol Psychiatry 2000; 47 15. Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram resides in the S ; - + ; -enantiomer. J Neural Transm Gen Sect 1992; 88: 157160 Wade A, Lemming MO, Hedegaard BK. Escitalopram 10 mg day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95102 Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331336 Gorman JM. Comparison of efficacy in placebo-controlled trials of escitalopram and citalopram [poster]. Presented at the 154th annual meeting of the American Psychiatric Association; May 510, 2001; New Orleans, La 19. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002; 7 suppl 1 ; : 4044 20. Kasper S, Loft H, Smith RJ. Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. Presented at the 23rd Congress of the Collegium Internationale NeuroPsychopharmacologicum; June 2327, 2002; Montreal, Canada 21. Stahl S, Gegel I, Li D. Escitalopram in the treatment of panic disorder. Presented at the 23rd Congress of the Collegium Internationale NeuroPsychopharmacologicum; June 2327, 2002; Montreal, Canada 22. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871880 Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind, placebo-controlled trial. J Clin Psychiatry 2002; 63: 225231 Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 383390 Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 308315 Lynch M. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001; 26: 3036 Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann Rev Neurosci 1984; 7: 309338. 2.1.3 Information to Consumers: Whenever supplying consumer medicines information CMI ; leaflets or other printed information to patients for medicines which are used off-label, it is important to ensure that patients are counseled about any inconsistencies which may appear in the CMI's or other printed information. This may prevent unnecessary confusion or concerns in patients. This issue is highlighted by a recent report in the ISMP Medication Safety Alert, where an elderly patient who had been prescribed amitriptyline for his neck pain, became angry with his physician for "misdiagnosing" his condition, as the leaflet did not mention that the medicine might be used to treat neuropathic pain29. Lack of awareness by patients of the indication for a medicine, has also resulted in diagnostic errors. Two patients who had been prescribed anticonvulsants for reasons other than epilepsy went on to develop blackouts. These blackouts were erroneously diagnosed as epilepsy. Misinterpretation of their anticonvulsant therapy treatment as evidence for epilepsy was a crucial factor in their misdiagnosis30. 2.1.4 Adverse Drug Reactions: Adverse drug reactions or interactions involving medicines used off-label and those imported under the Personal Import Scheme, should be reported to ADRAC using the blue cards or the on-line facility in the usual manner. 2.1.5 Implications Post Hospital Discharge: As medicines are only available on the PBS for labeled uses approved indication, dosage, age and route ; , patients may be considerably disadvantaged financially if they have been prescribed medicines for off-label use. Wherever possible, implications should be discussed with patients prior to initiation of the medication and remeron. 2002 AstraZeneca: A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and ActiveControlled Study of SYMBICORTTM pMDI Administered Once Daily in Adults and Adolescents with Asthma-STEM CRO: PPD Eisai, Inc.: A 20-Week, Multi-Center, Randomized, Double-Blind Comparison of the Efficacy and Safety of Aricept Versus Inderal LA in Migraine Prophylaxis CRO: Inc. Research Eisai: A 12 Week, Double Blind Study in Patients with Mild to Moderate Alzheimer's Disease Who Either Continue Ongoing Donepezil Therapy or Switch to Galantamine Hydrobromide EpiCept Corporation: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Two Different Doses of EpiCept-NP Topical Cream ketamine & amitriptyline combination ; Applied Four Times Daily in the Treatment of Post Herpetic Neuralgia PHN ; CRO: INC Research Forest Laboratories, Inc.: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer's Type Forest Laboratories, Inc.: Double-Blind Flexible Dose Comparison of the Safety and Efficacy of Neramexane and Placebo in the Treatment of Major Depressive Disorder GlaxoSmithKline: A Multicenter, Double-Blind, Randomized, Study to Evaluate the Efficacy of Lamotrigine 200 mg day, 300 mg day, and 400 mg day Compared with Placebo in Subjects with Painful Diabetic Neuropathy CRO: PPD GlaxoSmithKline: A Multicenter, Double-Blind, Randomized, Study to Evaluate the Efficacy of Lamotrigine 200 mg day, 300 mg day, and 400 mg day Compared with Placebo in Subjects with Painful Diabetic Neuropathy CRO: PPD Lilly: Duloxetine One-Daily Dosing Versus Placebo in Patients with Major Depression and Pain Mylan Pharmaceuticals, Inc.: A Prospective, Randomized, Placebo-Controlled, Parallel Groups Study of the Continued Efficacy and Safety of Subcutaneous Injections of Apomorphine in the Treatment of "Off" Episodes in Patients With "On-Off" or "Wearing-Off " Effects Associated with Late-Stage Parkinson's Disease After Apomorphine Use for at Least a Three Month Duration Novartis Pharmaceuticals Corporation: An open-label, multicenter, sequential cohort study prospectively evaluating the tolerability and safety of switching patients from Aricept donepezil ; 10 mg day to Exelon rivastigmine ; 1.5 mg bid CRO: PRA International NJ ; Novartis Pharma AG: An international, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, 52-week gastrointestinal clinical safety study to demonstrate that COX 189 400 mg od ; reduces the risk to develop complicated ulcers as compared to NSAIDs naproxen 500 mg bid and ibuprofen 800 mg tid ; , in osteoarthritis patients Organon Inc. Akzo Nobel ; : A Double-blind, Multi-center, Randomized, Placebo-controlled, Efficacy and Safety Study of Org 33062 ER and Fluoxetine in Subjects with Major Depressive Disorder. Drug Carbamazepine Ethosuximide Phenobarbital Phenytoin sodium Sodium Valproate Amitriptyline Chlorpromazine Diazepam Fluphenazine Haloperidol Lithium Biperiden Carbidopa Levodopa * cost of single injectible unit Availability yes no yes no yes no no yes yes yes no no no yes 125 12.74 25 * 304 500 24.06 Commonest Strength mg ; 400 Approximate cost in USD of 100 tablets of the commonest strength 22.65 and elavil. Koelega, H. S., Stimulant drugs and vigilance performance: A review, Psychopharmacology, 111, 1, 1993. McNair, D. M., Antianxiety drugs and human performance, Archives of General Psychiatry, 29, 611, 1973. Heishman, S. J., Taylor, R. C., and Henningfield, J. E., Nicotine and smoking: A review of effects on human performance, Experimental and Clinical Psychopharmacology, 2, 345, 1994. Foltin, R. W. and Evans, S. M., Performance effects of drugs of abuse: A methodological survey, Human Psychopharmacology, 8, 9, 1993. Hindmarch, I., Psychomotor function and psychoactive drugs, British Journal of Clinical Pharmacology, 10, 189, 1980. Nicholson, A. N. and Ward, J., Eds., Psychotropic drugs and performance, British Journal of Clinical Pharmacology, 18, 1S, 1984. Beardsley, P. M. and Kelly, T. H., Acute effects of cannabis on human behavior and CNS function: Update of experimental studies, in press. 11. Chait, L. D. and Pierri, J., Effects of smoked marijuana on human performance: A critical review, in Marijuana Cannabinoids: Neurobiology and Neurophysiology, Murphy, L. andBartke, A., Eds., CRC Press, Boca Raton, 1992, 387. 12. Curran, H. V., Benzodiazepines, memory and mood: A review, Psychopharmacology, 105, 1, 1991. Ghoneim, M. M. and Mewaldt, S. P., Benzodiazepines and human memory: A review, Anesthesiology, 72, 926, 1990. Koelega, H. S., Benzodiazepines and vigilance performance: A review, Psychopharmacology, 98, 145, 1989. Sherwood, N., Effects of nicotine on human psychomotor performance, Human Psychopharmacology, 8, 155, 1993. Zacny, J. P., A review of the effects of opioids on psychomotor and cognitive functioning in humans, Experimental and Clinical Psychopharmacology, 3, 432, 1995. Gavin, F. H. and Ellinwood, E. H., Cocaine and other stimulants: Actions, abuse, and treatment, New England Journal of Medicine, 318, 1173, 1988. Jaffe, J. H., Drug addiction and drug abuse, in The Pharmacological Basis of Therapeutics, Gilman, A. G., Rall, T. W., Nies, A. S., and Taylor, P., Eds., Pergamon Press, New York, 1990, 522. 19. Fischman, M. W. and Schuster, C. R., Cocaine self-administration in humans, Federation Proceedings, 41, 241, 1982. Woolverton, W. L., Kandel, D., and Schuster, C. R., Tolerance and cross-tolerance to cocaine and d-amphetamine, Jounral of Pharmacology and Experimental Therapeutics, 205, 525, 1978. Derlet, R. W., Rice, P., Horowitz, B. Z., and Lord, R. V., Amphetamine toxicity: Experience with 127 cases, Journal of Emergency Medicine, 7, 157, 1989. Myerson, A., Effect of benzedrine sulphate on mood and fatigue in normal and in neurotic persons, Archives of Neurology and Psychiatry, 36, 816, 1936. Smith, J. M. and Misiak, H., Critical Flicker Frequency CFF ; and psychotropic drugs in normal human subjects - a review, Psychopharmacology, 47, 175, 1976. Farre, M., de la Torre, R., Llorente, M., Lamas, X., Ugena, B., Segura, J., and Cami, J., Alcohol and cocaine interactions in humans, Journal of Pharmacology and Experimental Therapeutics, 266, 1364, 1993. Peck, A. W., Bye, C. E., Clubley, M., Henson, T., and Riddington, C., A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects, British Journal of Clinical Pharmacology, 7, 469, 1979. Bye, C., Munro-Faure, A. D., Peck, A. W., and Young, P. A., A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests, European Journal of Clinical Pharmacology, 6, 163, 1973. Evans, M. A., Martz, R., Rodda, B. E., Lemberger, L., and Forney, R. B., Effects of marihuanadextroamphetamine combination, Clinical Pharmacology and Therapeutics, 20, 350, 1976. Hamilton, M. J., Smith, P. R., and Peck, A. W., Effcts of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electroencephalogram in healthy volunteers, British Journal of Clinical Pharmacology, 15, 367, 1983. The reason amitriptyline would be the choice in the hypothetical scenario is precisely the same reason that we tend to avoid it when treating a patient with an uncomplicated form of major depression in conventional practice and endep. 512 c ; 2 ; f ; iii ; of the federal food, drug, and cosmetic act. AMINO ACID ANALYSIS, QUANTITATIVE, URINE. [RAAUR]. Draw: 24 hour or random 4 hour fasting ; urine collection. Keep refrigerated during collection. No preservative. Note: Provide the same information listed for the AMINO ACID ANALYSIS, QUALITATIVE, PLASMA. Lab: 10 ml frozen aliquot of 24 hour or random 4 hour fasting ; urine collection 2 ml minimum ; . Ref Lab: Quest Aminophylline. See THEOPHYLLINE LEVEL. AMIODARONE. [RAMIO]. Aliases: Cordarone, Desethylamiodarone Draw: 10 ml plain red top tube minimum 5 ml whole blood ; . Do not use gel barrier tubes. Lab: 3 ml serum minimum 1.1 ml ; . Ship refrigerated. Ref Lab: Quest AMITRIPTYLINE Elavil ; includes Nortriptyline ; . [RAMIT]. Aliases: Amitril, Elavil, Etrafon, Eudep, Limbitrol, Triavil Draw: 10 ml plain red top tube minimum 5 ml whole blood ; . Do not use gel barrier tubes. Lab: 3 ml serum 1.5 ml minimum ; . Separate cells ASAP. Ship refrigerated. Ref Lab: Quest AMMONIA, BLOOD. [AMM]. Draw: Fast 6 hours. Avoid hemolysis & fist clenching. Draw 5 ml EDTA tube 3 ml minimum ; . Cool on ice. All specimens must be transported to the Lab immediately on ice. Nursery minimum specimen: 1 ml EDTA whole blood. Lab minimum: 300 mcl plasma. Note: Avoid ammonium heparin. Na or Li okay. Lab: Minimum 0.5 ml plasma. Centrifuge & remove plasma within 30 min. Amniotic Fluid L S Ratio includes L S Ratio & PG phosphatidylglycerol ; . See L S Ratio. AMNIOTIC FLUID SCAN. Delta OD 450 ; [RAMNIO]. Draw: 3 ml amniotic fluid 2ml minimum ; . Note: Optical density method. Lab: Store at refrigerated temperature up to 3 hours or freeze for longer storage. Protect from light. Request phoned report. ALWAYS PACKAGE IN STAT BAG. Ref Lab: Quest AB ; Order on a manual requisition! Amobarbital. See BARBITURATES. Amoeba Antibody [REHIST]. See: E. Histolytica Amebiasis, parasite, wet mounts, & stained slide. See O & P. Amphetamines Qual. Order Drugs of Abuse, Urine. AMPHETAMINES URINE QUAL. CONFIRMATION. [RAMPLU]. Draw: Random urine 25 ml minimum ; . Note: Ordered by Lab only when indicated by positive urine drugs of abuse screen. Lab: 10 ml aliquot of random urine 3-5 ml minimum ; . Ship refrigerated. Ref Lab: Quest AMYLASE, FLUID. [FAMY]. Draw: 1.5 ml body fluid. Note: State type of fluid. AMYLASE ISOENZYMES Fractionation ; . [RAMYI]. Aliases: Fractionated Isoenzymes, Pancreatic Amylase, Salivary Amylase Draw: 10 ml red top tube minimum 8 ml whole blood ; or 5 ml gel gold. Note: To distinguish pancreatic & salivary isoenzymes. Will detect macroamylasemia. Lab: 1 ml serum 0.5 ml minimum ; . Refrigerate specimen. Ref Lab: Quest AMYLASE. [AMY] Draw: 4 ml gel green top tube 3 ml minimum whole blood ; Note: Cholangiography may spuriously elevate. Lab: 1 ml heparinized plasma minimum 0.5 ml ; . AMYLASE, URINE. [UAMYT]. Draw: Collect timed 2 hour urine. Have patient void & discard this urine; have patient drink glass of water. After 2 hours patient voids completely & all of the specimen is sent to Lab. Lab: Record 2 hour volume and citalopram and Cheap amitriptyline. 2.3.3 Adverse events of Peg-IFN Peg-IFN has been used for the treatment of chronic hepatitis C CHC ; , HIV-1, CML, solid tumors including melanoma and renal cell cancer ; , and multiple sclerosis MS ; . Dosing exposure has ranged from 0.035 to 9.0 g kg week. Treatment duration has been as long as 1 year in CHC, CML, and solid tumors, as long as 7 months in HIV-1, and as long as 6 months in MS. The safety profile of Peg-IFN appears to be similar across all indications and consistent with the safety profile of IFN. The most frequent reported adverse events with Peg-IFN are headache, fatigue, fever, myalgia, and arthralgia. There appears to be an IFN dose-independent increase in the incidence of most of the flu-like effects. Psychiatric events are recognized problems with IFN and have a similar incidence with Peg-IFN. The incidence does not appear to be dose-related. Application site disorder injection site inflammation and injection site reaction ; is common with PegIFN, but it is generally mild to moderate and not treatment limiting. In oncology clinical trials, in which a dose of 6.0 g kg week was administered, Grade 3 elevations in hepatic enzymes 5 to 20 times the upper limit of normal ; have been observed. Dose-related decreases in leukocyte, neutrophil, and platelet counts are associated with both Peg-IFN and IFN, but these can be managed with dose modification. Amitriptyline hcl 25mg tab sanSSRIs selectively block the reuptake of serotonin in the presypnaptic bulb, and are reported to have a lower incidence of side effects compared with TCAs. One study demonstrated that paroxetine 40 mg day was effective for painful diabetic neuropathy.23 In a double-blind, placebocontrolled, crossover study, citalopram 40mg day was shown to provide slight relief of the symptoms of chronic diabetic neuropathy.24 In a trial comparing desipramine with amitriptyline, and fluoxetine with placebo, Max et al found that fluoxetine 40 mg day did not appear to be effective for pain in diabetic neuropathy, while amitriptyline and desipramine were each effective, to a similar degree.12 The findings supported the hypothesis that the inhibition of the reuptake of noradrenaline may account for the analgesic effect of TCAs. The blockade of serotonin reuptake by amitriptyline might augment the analgesic effect.12, 25 In similar fashion to claims regarding antidepressant effects, an enhanced analgesic effect of other antidepressants with dual actions was proposed. TRADITIONAL CHINESE MEDICINE The clinical characteristics of SARS are mainly manifested as prominent symptoms due to noxious heat and pathogenic dampness in most cases, which may lead to the rapid exhaustion of yin-qi and body fluids, and severe complications. Accordingly, the preventive strategy against SARS is to clear away the lung heat and toxic substances, to remove the pathogenic dampnes's by aromatics and to supplement qi and promote the production of body fluids. Prevention and treatment protocol for SARS and suspected cases by State Administration of Traditional Chinese Medicine of China In order to improve the curative effects on the basis of recommended treatment protocol for SARS or suspected cases and discharge criteria by Ministry of Public Health, the following therapeutic approaches of the traditional Chinese medicine are proposed to be used in the anti-SARS treatment. It is recommended that the therapeutic principles of traditional Chinese medicine, namely diagnosis and treatment based on an overall analysis of the illness and the patient's condition, should be performed in the treatment of SARS and suspected cases. Meanwhile, the treatment protocols should be adjusted as the patient's condition changes. In the early phase, the SARS patients are characterized by the impairment of pulmonary function due to noxious heat and stagnation of damp-heat, which are symptomatically categorized into 3 types of pulmonary impairment due to noxious heat, stagnation of damp heat and exterior cold and interior heat with dampness. For the cases manifested as pulmonary impairment due to noxious heat, it is suitable to promote pulmonary function by eliminating toxic heat via activating superficial channels and choosing a modified prescription of Yinqiao Powder plus Maxing Shigan Decoction. For the patients displaying stagnation of damp-heat, it is recommended to disperse the pathogenic factor out of the body by a revised recipe of Sanren Decoction plus Shengjiang Powder. When the condition is dominated by more dampness and less heat in these cases, Huopu Xialing Decoction should be adopted. For those with a manifestation of exterior cold. 'source: division of tuberculosis control, san francisco health department and buy abilify. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: PAR MDUK 032 Title: A Double Blind Study to Compare the Efficacy and Tolerability of Paroxetine and Amitriptyline in a Multi-Centre General Practice Study in Depressed Patients Rationale: Paroxetine has been developed as an antidepressant that may have potential advantages in terms of safety and tolerability over less specific agents such as tricyclic antidepressants. This study was conducted to compare the efficacy and tolerability of paroxetine with that of amitriptyline, a tricyclic agent, in patients with depression. Phase: Phase III Study Period: August 1985 to September 1986 Study Design: Randomized, double blind, double dummy, six-week parallel group comparative study, followed by an optional open study of paroxetine. Centres: Multi-centre general practice study. Indication: Major Depressive Disorder Treatment: Once subjects were randomized into either the paroxetine or amitriptyline groups, active study medication was administered. During Days 1-4 subjects in the paroxetine group took one 20mg paroxetine tablet in the morning and 1 placebo PBO ; amitriptyline tablet in the evening. From Day 5 onward, paroxetine subjects took one 30mg paroxetine tablet in the morning and varying doses 1-3 tablets ; of PBO amitriptyline in the evening, according to the therapeutic response and whether any side effects were experienced. Subjects in the amitriptyline group took one PBO paroxetine tablet in the morning throughout the study. On Days 1-7 amitriptyline subjects took one 50mg amitriptyline tablet in the evening. During Days 8-14 amitriptyline subjects took one or two 50mg amitriptyline tablets in the evening, and from Day 15 onward, two to three 50mg amitriptyline tablets in the evening, again according to response and tolerability. Objectives: To compare the efficacy and tolerability of paroxetine 20 to 30mg daily, with that of amitriptyline 100 to 150mg daily in subjects with depression and to assess the speed of onset of action of the two treatment regimes. Primary Outcome Efficacy Variable: The 21 item Hamilton Depression Rating Scale HAMD-21 ; total score and Physician's Global Assessment of Severity of Illness after 6 weeks were the primary efficacy variables. Secondary Outcome Efficacy Variable s ; : The HAMD-21 sub-factors were considered secondary endpoints. Statistical Methods: The main analyses were carried out on the intent-to-treat population using the extender dataset a dataset that has missing values imputed by last-observation-carried-forward. Differences in the HAMD-12 total score were analyzed using a Student's t-test. A Mann-Whitney U-Test was used to analyze differences in the Physician's Global Assessment of Severity of Illness. Tests were done at the two-sided 5% significance level. Study Population: Male or female subjects aged 18 to 75 years, suffering from reactive or endogenous unipolar depression fulfilling the Diagnostic and Statistical Manual of Mental Disorders criteria 296.2 and 296.3 DSM-III ; , considered suitable for treatment with anti-depressant drugs, and also having a minimum score of 17 on the first 17 items of the HAMD-21, were eligible for inclusion in the study. Number of Subjects: Paroxetine Amitriptyline Planned, N Not available Not available Entered, N 29 30 Completed, n % ; 19 66 ; 20 Total Number Subjects Withdrawn, N % ; 10 34 ; 10 Withdrawn due to Adverse Events n % ; 9 31 ; Withdrawn due to Lack of Efficacy n % ; 0 0 Withdrawn for other reasons n % ; 1 3 ; Demographics: Paroxetine Amitriptyline N 29 N ITT ; 29 30 Females: Males 21: 8 22: Mean Age, years sd ; 42.6 11.7 ; 46.2 11.8 ; White, n % ; 29 100 ; 29 97 ; Primary Efficacy Results ITT ; : Because of the small number of subjects in this study efficacy data was not summarized. A t o automated method has been developed f o r analysis of tricyclic antidepressant drugs TCADs ; in serum using a programmable on-line solid phase extraction technique PR05PEKT ; . The clean-up of TCAD serum samples was performed on disposable cyanopropyl preeolumns which were automatically exchanged before every analysis. For selective isolation the clean-up solvent was optimised with respect to pH and percentage modifier. The optimum clean-up solvent was 20~ acetonitrile in 0 . borate buffer. Recoveries For amitriptyline its metabolite nortriptyline and the internal standard imipramine were ranging From 90 to 93%. Less than 5% loss of plates was observed using on-line clean-up in the foreflush mode as compared to direct injection on the analytical column. Linearity of response in the therapeutic concentration range as defined by the c o r coefficients o f the regression lines was better than 0.9995 For all drugs. Reproducibility of analysis was found to be 3.1~ CV n lO ; influence of cartridge exchange on reproducibility was observed. Maximum loading capacities For 2 and 3 mm ID precolumns were 600 and 800 ut serum respectively. The limit of detection was Found to be 1 - ml. SPARK HOLLAND 8 . V The N e t P.O. Box ; 88, 7800 A3 EMMEN. Death Drive". Sponsored by the Baltimore Washington Society for Psychoanalysis, bwanalysis or call 410-792-8060 or 301-470-3635. For Rent - Spacious downtown office available at 3 Washington Circle Medical Building ; . Share suite with five other MH professionals MD, Ph.D., MSW ; . Full or part time. 202-775-1182 RESTON VA Room available for part-time use in a suite of mental health professionals on the grounds of Reston Hospital. Room is without a window but is good-sized and offers the opportunity for working in close proximity to other independent mental health professionals in a part of Reston that is booming! If interested, call Dr. Novacki at 703 ; 437-8045. McLean VA Great location in McLean, Virginia. Close to Tysons Corner and public transportation. Building has many amenities. Call Kathleen Salyer, Ph.D. 703 ; 734-1393 WHITE FLINT, MD Spacious, sunny, large-windowed, furnished 2office suite in luxurious, secure office building. Across from White Flint Mall + Metro. Share waiting room, work room with copier, fridge, microwave, and separate exit door. Available part time immediately. Call Joan Goodman LCSW-C 301 ; 881-0433 Bethesda Office space available in Wyngate Medical Park. Close to NIH. Free Parking. Separate office with shared waiting area with two psychiatrists in 3-office suite. Fulltime or part-time. Please call Kathryn Suter, MD at 301-897-9693 or Al Zachik, MD at 301-530-4664. Office for rent in 4-office psychotherapy suite in upper NW D.C. Connecticut and Albemarle ; . Sunny, comfortable office with closet; reasonable rent. Available August 19th. Please call 202 ; 244-6446. PSYCHIATRIST WANTED F T, P T, B psychiatrist needed in the Prince George's County, Maryland area and Greater Southeast, Washington DC area. Send resume and salary requirements to Tina Miller, 7910 Andrus Rd., Ste. 16, Alexandria, VA 22306, phone 703 ; 780-9465, Fax: 703 ; 780-9359. The seminar "I, Too, Sing America: Culturally Informed Psychotherapeutic Practice" will be presented October 15 and 16 at the Baltimore Washington Center for Psychoanalysis, from 9: 00 a.m. to 4: 30 p.m. Marilyn Martin, MD, MPH, will lead the seminar. Dr. Martin is a public health physician with a practice of psychiatry and psychoanalysis in Baltimore; she lectures nationally on issues of cultural diversity, spirituality, and mental health literacy. Registration is 0. Participants will be eligible for 12 CEUs 12 CMEs. For more information see bwanalysis or call 310-470-3635 or 410-792-8060. Percent of baby boomers say the signs of aging they notice first are graying hair and balding; 22 percent, poor eyesight; 13 percent, weight gain; 11 percent, wrinkles; 3 percent, age spots; and 2 percent, memory loss. Amitriptyline is contraindicated in patients who have shown prior hypersensitivity to it. Monoamine Oxidase Inhibitors MAOIs ; Endep should not be given concurrently with monoamine oxidase inhibitors, including selegiline. The combination of amitriptyline with a monoamine oxidase inhibitor has caused severe convulsions, hyperpyretic crises and death. When it is desired to substitute amitriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. Amitriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. Cisapride Amitriptyline is contraindicated in patients taking cisapride due to the possibility of adverse cardiac interactions including prolongation of the QT interval, cardiac arrhythmias and conduction system disturbances. Myocardial Infarction Amitriptyline is not recommended for use during the acute recovery phase following myocardial infarction. See Precautions, Use in Pregnancy and Use in Lactation. Amitriptyline tablets 25mgAmitriptuline, amitriphyline, amitriptylone, am8triptyline, amitriltyline, amitrptyline, amitriptylinw, anitriptyline, amirtiptyline, amitriptylline, amitriptjline, amitriptylinne, amitiptyline, amitgiptyline, amitripttline, amitfiptyline, amitriiptyline, ami6riptyline, amtriptyline, amltriptyline, mitriptyline, amitruptyline, amitriptlyine, amitri0tyline, amihriptyline, amitriptylime, amitripytline, amitripthline, amitripyyline, wmitriptyline, amitriptylune, amitriotyline, amitripfyline, amitriptylin, amitriptyl9ne, amiteiptyline, xmitriptyline, amitriptyine, amitriptylin3, amitriptypine, amitriptylien, amitripttyline, amit5iptyline, aamitriptyline, amitriptylind, ammitriptyline, smitriptyline, amitriptyllne, maitriptyline, amitripptyline, amitriptylibe, amifriptyline, amitriptylkne, zmitriptyline, amit4iptyline, aitriptyline.Amitriptyline pill imageAmitriptyline hcl 25mg tab san, amitriptyline tablets 25mg, amitriptyline pill image, amitriptyline muscle cramps and chlordiazepoxide amitriptyline hcl. Amitriptyline side affects, amitriptyline hcl 25mg apothecon, amitriptyline side effects in children and amitriptyline zoeken or amitriptyline dose for depression. Amitriptyline muscle crampsGlutamine 1000mg, exophthalmos more for_patients, human growth releasing hormone, permanent makeup knoxville and group therapy names. Bartter syndrome wiki, orbital virtual terminal, diabetic retinopathy mechanism and courier final draft font or prolactin headaches.
© 2009 |
